A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 given in Combination with Gemcitabine in Subjects with Metastatic Pancreatic Cancer
The purpose of this study is to determine whether or not the antibody experimental drug AGS-1C4D4 in combination with the cancer drug gemcitabine is safe and whether it can extend a patient’s life up to 6 months. This research study is for people with metastatic pancreatic cancer.
Principal Investigator: Dr. Jay Rhee – (410)573-5300
Clinical Coordinator: Emily Ross – (410)571-1827
GS-US-324-0101: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
http://clinicaltrials.gov/ct2/results?term=PANCREATIC+GS+6624+MARYLAND&recr=&rslt=&type=&cond=&intr=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e= Principle Investigator: Dr. Jay Rhee, MD. (443)-571-5300
Research Staff: Emily Ross, CRCC (443)-481- 4392